Cell Therapy News

Kite Pharma submitted a supplemental biologics license application to the FDA that seeks expanded approval of axicabtagene ciloleucel.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

The world of cancer cell therapy continues to evolve, and the next breakthrough may include T cells genetically modified to include T-cell receptors that recognize a wider array of tumor-associated antigens.

Patients with diffuse large B-cell lymphoma who achieved a durable response to axicabtagene ciloleucel showed evidence of lower circulating tumor DNA levels before and after treatment, according to results of a prospective study.

September is Blood Cancer Awareness Month.

COVID-19 variants pose a greater threat to certain patients with cancer, particularly those with hematologic malignancies, confirming the need to promote vaccination within this population, according to data presented at ESMO Congress 2021.

The FDA granted fast track designation to CT-0508 for treatment of patients with solid tumors that overexpress human epidermal growth factor receptor 2.

The FDA received a completed rolling biologics license application for betibeglogene autotemcel, a gene therapy in development to treat patients with transfusion-dependent beta-thalassemia.

More than a third of patients with solid tumors showed evidence of antitumor response after treatment with ADP-A2M4CD8, according to data presented at the virtual ESMO Congress.

The FDA cleared an investigational new drug application for NTLA-5001, a T-cell receptor T-cell therapy designed to treat adults with relapsed or refractory acute myeloid leukemia.